

# Daniel Batlle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5209542/publications.pdf>

Version: 2024-02-01

128  
papers

8,991  
citations

47006

47  
h-index

42399

92  
g-index

131  
all docs

131  
docs citations

131  
times ranked

10348  
citing authors

#	ARTICLE	IF	CITATIONS
1	Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2002, 347, 797-805.	27.0	667
2	Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1380-1383.	6.1	453
3	Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting Enzyme. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3067-3075.	6.1	439
4	Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. <i>American Journal of Medicine</i> , 2003, 115, 291-297.	1.5	416
5	Renin-Angiotensin System Blockers and the COVID-19 Pandemic. <i>Hypertension</i> , 2020, 75, 1382-1385.	2.7	412
6	Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?. <i>Clinical Science</i> , 2020, 134, 543-545.	4.3	369
7	Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. <i>Kidney International</i> , 2003, 63, 1483-1490.	5.2	331
8	Antiproteinuric effect of oral paricalcitol in chronic kidney disease. <i>Kidney International</i> , 2005, 68, 2823-2828.	5.2	326
9	Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2. <i>Hypertension</i> , 2010, 55, 90-98.	2.7	273
10	ACE and ACE2 Activity in Diabetic Mice. <i>Diabetes</i> , 2006, 55, 2132-2139.	0.6	270
11	Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic Mice. <i>Hypertension</i> , 2004, 43, 1120-1125.	2.7	206
12	Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 263-276.	1.9	198
13	Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, F398-F405.	2.7	188
14	Genetic causes and mechanisms of distal renal tubular acidosis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3691-3704.	0.7	163
15	Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyl oligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent. <i>Hypertension</i> , 2020, 75, 173-182.	2.7	155
16	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor. <i>Hypertension</i> , 2020, 76, 1339-1349.	2.7	147
17	Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4273-4287.	0.7	131
18	Angiotensin II Activation of Cyclin D1-dependent Kinase Activity. <i>Journal of Biological Chemistry</i> , 1996, 271, 22570-22577.	3.4	130

#	ARTICLE	IF	CITATIONS
19	High CO <sub>2</sub> Levels Impair Alveolar Epithelial Function Independently of pH. PLoS ONE, 2007, 2, e1238.	2.5	108
20	Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney International, 2012, 81, 520-528.	5.2	105
21	ACE2 alterations in kidney disease. Nephrology Dialysis Transplantation, 2013, 28, 2687-2697.	0.7	105
22	Angiotensin-Converting Enzyme 2-Independent Action of Presumed Angiotensin-Converting Enzyme 2 Activators. Hypertension, 2014, 63, 774-782.	2.7	101
23	Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney International, 2012, 82, 292-303.	5.2	98
24	Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies. American Journal of Medicine, 1982, 72, 188-192.	1.5	97
25	ACE2 and Diabetes: ACE of ACEs?. Diabetes, 2010, 59, 2994-2996.	0.6	95
26	Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 1941-1943.	6.1	95
27	Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney International, 2018, 94, 114-125.	5.2	94
28	Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney International, 2003, 63, 217-224.	5.2	93
29	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nature Communications, 2022, 13, 405.	12.8	92
30	Murine Recombinant Angiotensin-Converting Enzyme 2. Hypertension, 2012, 60, 730-740.	2.7	89
31	Hypoxia Stimulates Osteopontin Expression and Proliferation of Cultured Vascular Smooth Muscle Cells. Diabetes, 2001, 50, 1482-1490.	0.6	83
32	A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. Journal of the American Society of Nephrology: JASN, 2021, 32, 795-803.	6.1	82
33	Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 714-716.	4.5	74
34	Hereditary Distal Renal Tubular Acidosis: New Understandings. Annual Review of Medicine, 2001, 52, 471-484.	12.2	69
35	Pharmacologic modulation of ACE2 expression. Current Hypertension Reports, 2008, 10, 410-4.	3.5	69
36	Distal renal tubular acidosis with intact capacity to lower urinary pH. American Journal of Medicine, 1982, 72, 751-758.	1.5	65

#	ARTICLE	IF	CITATIONS
37	Biological Variability of Estimated GFR and Albuminuria in CKD. American Journal of Kidney Diseases, 2018, 72, 538-546.	1.9	62
38	Regulation of urinary ACE2 in diabetic mice. American Journal of Physiology - Renal Physiology, 2013, 305, F600-F611.	2.7	60
39	Evaluation of Renal Hypoxia in Diabetic Mice by BOLD MRI. Investigative Radiology, 2010, 45, 819-822.	6.2	59
40	ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney. Physiological Reports, 2014, 2, e00264.	1.7	58
41	Distal nephron function in patients receiving chronic lithium therapy. Kidney International, 1982, 21, 477-485.	5.2	57
42	Na <sup>+</sup> /H <sup>+</sup> exchange activity and NHE-3 expression in renal tubules from the spontaneously hypertensive rat. Kidney International, 2002, 62, 157-165.	5.2	56
43	Cuffless Blood Pressure Monitoring. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1531-1538.	4.5	56
44	Evidence For and Against Direct Kidney Infection by SARS-CoV-2 in Patients with COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1755-1765.	4.5	54
45	Osteopontin mediates hypoxia-induced proliferation of cultured mesangial cells: Role of PKC and p38 MAPK. Kidney International, 2000, 58, 691-700.	5.2	52
46	Distal Renal Tubular Acidosis and the Potassium Enigma. Seminars in Nephrology, 2006, 26, 471-478.	1.6	52
47	Distal Renal Tubular Acidosis: Pathogenesis and Classification. American Journal of Kidney Diseases, 1982, 1, 328-344.	1.9	51
48	Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy. Kidney International, 2017, 91, 1336-1346.	5.2	49
49	Apelin and ACE2 in cardiovascular disease. Current Opinion in Investigational Drugs, 2010, 11, 273-82.	2.3	49
50	Acid-Base and Potassium Disorders in Liver Disease. Seminars in Nephrology, 2006, 26, 466-470.	1.6	46
51	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System. Hypertension, 2020, 76, 1350-1367.	2.7	46
52	Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2008, 24, 526-534.	0.7	45
53	Effect of Insulin on ACE2 Activity and Kidney Function in the Non-Obese Diabetic Mouse. PLoS ONE, 2014, 9, e84683.	2.5	45
54	Hypokalemic Distal Renal Tubular Acidosis. Advances in Chronic Kidney Disease, 2018, 25, 303-320.	1.4	43

#	ARTICLE	IF	CITATIONS
55	The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation. <i>FASEB Journal</i> , 2020, 34, 10505-10515.	0.5	41
56	Underlying defects in distal renal tubular acidosis: New understandings. <i>American Journal of Kidney Diseases</i> , 1996, 27, 896-915.	1.9	40
57	Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. <i>Journal of Molecular Medicine</i> , 2017, 95, 473-486.	3.9	40
58	Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System. <i>Biomolecules</i> , 2019, 9, 886.	4.0	39
59	Angiotensin-converting enzyme 2 and the kidney. <i>Experimental Physiology</i> , 2008, 93, 549-556.	2.0	38
60	Angiotensinogen as a biomarker of acute kidney injury. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 759-768.	2.9	37
61	Growth phenotype of cultured skin fibroblasts from IDDM patients with and without nephropathy and overactivity of the Na <sup>+</sup> /H <sup>+</sup> antiporter. <i>Kidney International</i> , 1996, 50, 1684-1693.	5.2	36
62	Urinary Renin in Patients and Mice With Diabetic Kidney Disease. <i>Hypertension</i> , 2019, 74, 83-94.	2.7	33
63	An update on ACE2 amplification and its therapeutic potential. <i>Acta Physiologica</i> , 2021, 231, e13513.	3.8	33
64	Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F487-F494.	2.7	32
65	New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 250-257.	2.0	30
66	Proximal renal tubular acidosis with and without Fanconi syndrome. <i>Kidney Research and Clinical Practice</i> , 2019, 38, 267-281.	2.2	30
67	A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. <i>American Journal of Kidney Diseases</i> , 1999, 33, 450-457.	1.9	29
68	Predominance of AT1 Blockade Over Mas-Mediated Angiotensin-(1-7) Mechanisms in the Regulation of Blood Pressure and Renin-Angiotensin System in mRen2.Lewis Rats. <i>American Journal of Hypertension</i> , 2013, 26, 583-590.	2.0	29
69	Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis. <i>American Journal of Hypertension</i> , 2015, 28, 1418-1426.	2.0	28
70	Renal Tubular Acidosis. <i>Medical Clinics of North America</i> , 1983, 67, 859-878.	2.5	27
71	A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1293-1307.	6.1	26
72	Clinical and cellular markers of diabetic nephropathy. <i>Kidney International</i> , 2003, 63, 2319-2330.	5.2	25

#	ARTICLE	IF	CITATIONS
73	The Urine Anion Gap in Context. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 195-197.	4.5	25
74	Hyperkalemic Forms of Renal Tubular Acidosis: Clinical and Pathophysiological Aspects. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 321-333.	1.4	25
75	Parathyroid hormone is not anticalciuric during chronic metabolic acidosis. <i>Kidney International</i> , 1982, 22, 264-271.	5.2	24
76	Angiotensin II and Renal Tubular Ion Transport. <i>Scientific World Journal, The</i> , 2005, 5, 680-690.	2.1	24
77	Acute Renal Failure from Adulteration of Milk with Melamine. <i>Scientific World Journal, The</i> , 2008, 8, 974-975.	2.1	24
78	Cross-Disciplinary Biomarkers Research. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 894-902.	4.5	24
79	Spherical nucleic acids as an infectious disease vaccine platform. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119093119.	7.1	20
80	Kidney Vacuolar H <sup>+</sup> -ATPase: Physiology and Regulation. <i>Seminars in Nephrology</i> , 2006, 26, 361-374.	1.6	19
81	Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting. <i>Pharmacological Reviews</i> , 2022, 74, 462-505.	16.0	18
82	Angiotensin-converting enzyme 2: Possible role in hypertension and kidney disease. <i>Current Hypertension Reports</i> , 2008, 10, 70-77.	3.5	17
83	A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13. <i>Scientific Reports</i> , 2017, 7, 45473.	3.3	17
84	Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity. <i>Cell</i> , 2022, 185, 1837-1839.	28.9	17
85	Comorbidity and Cardiovascular Risk Factors in Patients With Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2002, 22, 494-506.	1.6	16
86	Metabolic Acidosis or Respiratory Alkalosis? Evaluation of a Low Plasma Bicarbonate Using the Urine Anion Gap. <i>American Journal of Kidney Diseases</i> , 2017, 70, 440-444.	1.9	16
87	Angiotensin II and Angiotensin-(1-7) Effects on Free Cytosolic Sodium, Intracellular pH, and the Na <sup>+</sup> -H <sup>+</sup> Antiporter in Vascular Smooth Muscle. <i>Hypertension</i> , 1996, 27, 72-78.	2.7	16
88	Angiotensin II Increases H <sup>+</sup> -ATPase B1 Subunit Expression in Medullary Collecting Ducts. <i>Hypertension</i> , 2005, 45, 818-823.	2.7	14
89	Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2200-2202.	0.7	14
90	ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. <i>Clinical Science</i> , 2020, 134, 2791-2805.	4.3	14

#	ARTICLE	IF	CITATIONS
91	Potential benefits of alkali therapy to prevent GFR loss: time for a palatable "solution"™ for the management of CKD. <i>Kidney International</i> , 2010, 78, 1065-1067.	5.2	13
92	Apelinergic system in the kidney: implications for diabetic kidney disease. <i>Physiological Reports</i> , 2018, 6, e13939.	1.7	13
93	Cultured skin fibroblasts as an in vitro model to assess phenotypic features in subjects with diabetic nephropathy. <i>American Journal of Kidney Diseases</i> , 2001, 38, 646-648.	1.9	12
94	Predicting the development of diabetic nephropathy and its progression. <i>Advances in Chronic Kidney Disease</i> , 2005, 12, 202-211.	1.4	12
95	The Colon as the Potassium Target: Entering the Colonic Age of Hyperkalemia Treatment?. <i>EBioMedicine</i> , 2015, 2, 1562-1563.	6.1	12
96	Snapshot Hemodynamics and Clinical Outcomes in Hypertension. <i>Hypertension</i> , 2016, 67, 270-271.	2.7	12
97	Cyclophilins A and B oppositely regulate renal tubular epithelial cell phenotype. <i>Journal of Molecular Cell Biology</i> , 2020, 12, 499-514.	3.3	12
98	Nocturnal hypertension: Will control of nighttime blood pressure prevent progression of diabetic renal disease?. <i>Current Hypertension Reports</i> , 2004, 6, 393-399.	3.5	11
99	Urinary Angiotensinogen: A Promising Biomarker of AKI Progression in Acute Decompensated Heart Failure: What Does It Mean?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1515-1517.	4.5	11
100	Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus. <i>Physiological Reports</i> , 2019, 7, e14242.	1.7	10
101	Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?. <i>Kidney International</i> , 2019, 96, 815-817.	5.2	9
102	Temporal profile of serum-induced S-phase entry and retinoblastoma protein phosphorylation in human skin fibroblasts. <i>Kidney International</i> , 1999, 56, 1282-1285.	5.2	7
103	Angiotensins and the Heart. <i>Hypertension</i> , 2015, 66, 260-262.	2.7	7
104	Circadian changes in blood pressure and their relationships to the development of microalbuminuria in type 1 diabetic patients. <i>Current Diabetes Reports</i> , 2002, 2, 539-544.	4.2	6
105	Emerging importance of ACE2 in external stratified epithelial tissues. <i>Molecular and Cellular Endocrinology</i> , 2021, 529, 111260.	3.2	6
106	Potential SARS-CoV-2 kidney infection and paths to injury. <i>Nature Reviews Nephrology</i> , 2022, 18, 275-276.	9.6	6
107	The Application of High Density Microarray for Analysis of Mitogenic Signaling and Cell-Cycle in the Adrenal. <i>Endocrine Research</i> , 2000, 26, 807-823.	1.2	5
108	Vascular Angiotensin-Converting Enzyme 2. <i>Circulation Research</i> , 2010, 107, 822-824.	4.5	5

#	ARTICLE	IF	CITATIONS
109	Single-cell RNA profiling of glomerular cells in diabetic kidney: a step forward for understanding diabetic nephropathy. <i>Annals of Translational Medicine</i> , 2019, 7, S340-S340.	1.7	5
110	Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study. <i>Nephron</i> , 2022, 146, 599-609.	1.8	5
111	Proximal Renal Tubular Acidosis and Hypophosphatemia Induced by Arginine. <i>Advances in Experimental Medicine and Biology</i> , 1982, 151, 239-249.	1.6	4
112	Rigor before speculation in COVID-19 therapy. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L1027-L1028.	2.9	3
113	Revisiting the renin-angiotensin system. <i>Molecular and Cellular Endocrinology</i> , 2021, 529, 111268.	3.2	3
114	Progressive Hypertension and Severe Left Ventricular Outflow Tract Obstruction. <i>Hypertension</i> , 2019, 74, 1216-1225.	2.7	2
115	Knockout of aminopeptidase A in mice causes functional alterations and morphological glomerular basement membrane changes in the kidneys. <i>Kidney International</i> , 2021, 99, 900-913.	5.2	2
116	CONNed in Pregnancy. <i>Hypertension</i> , 2021, 78, 241-249.	2.7	2
117	Guest editorial: Diabetic kidney disease. <i>Advances in Chronic Kidney Disease</i> , 2005, 12, 126-127.	1.4	1
118	Physiologic Principles in the Clinical Evaluation of Electrolyte, Water, and Acid-Base Disorders. , 2008, , 2113-2141.		1
119	Physiologic Principles in the Clinical Evaluation of Electrolyte, Water, and Acid-Base Disorders. , 2013, , 2477-2511.		1
120	The Use of Bedside Urinary Parameters in the Evaluation of Metabolic Acidosis. , 2016, , 39-51.		1
121	COVID-19 and its impact on the kidney and the nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, i1-i5.	2.9	1
122	Serum potassium changes during hypothermia and rewarming: a case series and hypothesis on the mechanism. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 827-834.	2.9	1
123	A functional analysis of angiotensin II targets through genome wide surveys. <i>American Journal of Hypertension</i> , 2001, 14, A147-A148.	2.0	0
124	Carlos Margarit-In Memoriam, 1950-2005. <i>Scientific World Journal, The</i> , 2006, 6, 318-352.	2.1	0
125	Renal Tubular Acidosis and the Nephrology Teaching Paradigm. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 301-302.	1.4	0
126	SuO007CYCLOPHILINS A AND B OPPOSITELY REGULATE RENAL TUBULAR EPITHELIAL CELL PHENOTYPE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0



#	ARTICLE	IF	CITATIONS
127	Authorsâ€™ Reply. Journal of the American Society of Nephrology: JASN, 2020, 31, 1918-1919.	6.1	0
128	Tribute to Lewis Landsberg: A Giant of Academic Medicine. Hypertension, 2022, 79, 291-292.	2.7	0